BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 14, 2003
View Archived Issues
FDA Panel Appears To Support Genzyme's BLA For Fabry Drug
BETHESDA, Md. - An FDA panel on Monday said Genzyme General's surrogate endpoint from its Phase III trial of Fabrazyme in Fabry disease patients is likely to predict a clinically meaningful effect. (BioWorld Today)
Read More
Elixir, Centagenetix Plan To Merge Complementary Aging Programs
Read More
Identifying, Isolating Adult Stem Cells Widens Path To Variety Of Futuristic Anticancer Treatments
Read More
Aventis Picks Five Eos Targets; Vaccine Deal Ends With 'Bang'
Read More
Amylin Files For $141.7M Public Offering From Shelf
Read More
BioFocus Enters Amgen Deal, Offers Warning On Financials
Read More
Other News To Note
Read More
Appointments And Advancements
Read More